Dr. Faller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Ave
Moakley, 3rd Floor
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Education & Training
Boston Children’s Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1981 - 1983
University of California (San Francisco)Residency, Internal Medicine, 1979 - 1981
Harvard Medical SchoolClass of 1979
Certifications & Licensure
CA State Medical License 1980 - Present
MA State Medical License 1982 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1989
Clinical Trials
- Phase II Randomized Trial:Arginine Butyrate Plus Standard Local Therapy in Patients With Refractory Sickle Cell Ulcers Start of enrollment: 1997 Sep 01
- Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus Start of enrollment: 1994 Dec 01
Publications & Presentations
PubMed
- 47 citationsA randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcersLillian McMahon, Hannah Tamary, Melissa Askin, Patricia Adams-Graves, Robert T. Eberhardt
British Journal of Haematology. 2010-12-01 - 10 citationsLong Terminal Repeat Regions from Exogenous but Not Endogenous Feline Leukemia Viruses Transactivate Cellular Gene ExpressionSajal Ghosh, Pradip Roy-Burman, Douglas V. Faller
Journal of Virology. 2000-10-15 - 56 citationsPhase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.Martin H. Voss, Michael S. Gordon, Monica M. Mita, Brian I. Rini, Vicky Makker
British Journal of Cancer. 2020-09-11
Abstracts/Posters
- Combination of Oral Nanatinostat (Nstat), a Novel Histone Deacetylase Inhibitor (HDACi), and the Oral Anti-Viral, Valganciclovir (VGCV), Is Active in Relapsed/Refracto...Douglas V. Faller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus PhysicianÍs Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary...Douglas V. Faller, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
ORYZON Announces First Patient in in NET, a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine CarcinomasJanuary 18th, 2023- ORYZON Presents Final Data from Phase IIa ALICE Trial in Unfit AML Patients with First-Line Treatment of Iadademstat and Azacitidine in Oral Presentation at ASH-2022December 12th, 2022
- ORYZON to Present Preliminary Blinded Aggregate Safety Data from Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality DisorderSeptember 16th, 2022
- Join now to see all
Grant Support
- Mechanisms Of Action And Signaling By Steroid Hormone AntagonistsNational Cancer Institute2009–2012
- Boston University Cross-Disciplinary Training In Nanotechnology For CancerNational Cancer Institute2010–2011
- Inducing Chromosomal Damage Responses In Pancreatic CancerNational Cancer Institute2009–2010
- Development Of An Oncogene-Targeted TherapeuticNational Cancer Institute2009
- RAS Oncoprotein-Targeted Therapy For CancerNational Cancer Institute2005–2009
- Signal Transduction By Androgen In Prostate CellsNational Cancer Institute2004–2007
- Development Of A Ras-Targeted Cancer TherapeuticNational Cancer Institute2004
- Control Of Cell Growth By Short-Chain Fatty AcidsNational Cancer Institute2000–2004
- Oral Therapeutic For Beta-ThalassemiaNational Institute Of Diabetes And Digestive And Kidney Diseases2003
- Oral Therapeutic For Inducing Fetal HemoglobinNational Heart, Lung, And Blood Institute2002–2003
- Oral Therapeutics For Viral MalignanciesNational Cancer Institute2002–2003
- Oncobiology Training ProgramNational Cancer Institute1994–2003
- Anti Viral Therapeutic For EBV MalignanciesNational Cancer Institute2001–2002
- Cancer Research CenterNational Cancer Institute1999–2002
- Arginine Butyrate For Treatment Of Leg Ulcer In Patients With Sickle Cell DiseaseNational Center For Research Resources2001
- Arginine Butyrate Therapy--Leg Ulcer In Sickle Cell DISENational Center For Research Resources2000
- Control Of Cell Growth By OncogenesNational Cancer Institute1991–2000
- Oral Agents To Induce Fetal HemoglobinNational Heart, Lung, And Blood Institute1999
- Oral Therapeutics For Viral MalignanciesNational Cancer Institute1999
- Molecular Basis Of Htlv1 Induced ArthropathyNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1997–1999
- Detection Of Premaligancy In Breast Biopsy SpecimensNational Cancer Institute1996
- Trans Activation Of B Cell Mitogen Cytokine Genes By HIVNational Cancer Institute1994–1996
- Isobutyramide For Increasing Fetal Hemoglobin In Beta GlobinopathiesNational Center For Research Resources1994–1995
- Clinical Trials Of Butyrate Analogs In Beta HemoglobinopathiesNational Center For Research Resources1994–1995
- Mechanisms Of Vasoocclusion In Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1994
- Mechanisms Of Vaso-Occlusion In Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1991–1993
- Mechanisms Of Vaso-Occlusion In Sickle Cell AnemiaNational Heart, Lung, And Blood Institute1990–1991
- Control Of Cell Growth By OncogenesNational Cancer Institute1990–1991
- Tumor-Specific CTL Recognition Of Transfected CellsNational Cancer Institute1985–1988
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
